Abstract
INVESTORS ARE A FICKLE BUNCH. IT CAN TAKE AS LITTLE AS ONE failure for Wall Street to write off a technology that only a few years earlier had been hyped as next big thing. Stock prices plummet, and funding becomes scarce for companies on the cutting edge of science. Such setbacks only serve to further delay a technology from fulfilling its promise. But history has shown that it takes only one success in the biotechnology sector for the money to come back. After a lengthy period in the doghouse, oligonucleotide-based antisense drugs appear to be making strides toward getting back into the good graces of both investors and potential development partners. It took several glancing blows and one heck of a sucker punch to fully shake the confidence of the investment community in oligonucleotide-based antisense therapeutics. A major hit came as early as 1998, when Gilead Sciences, a pioneer in the ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
